Exercise News and Research

Latest Exercise News and Research

Fourth-quarter and fiscal year end 2009 results announced by Noveko International

Noveko International Inc. ("the Company") today announces the financial results for its fourth quarter and fiscal year ended June 30, 2009.

25 Sep 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

ACP releases paper promoting increased funding for FDA

A new policy paper that calls for broader authority and increased funding for the Food and Drug Administration (FDA) was released today by the American College of Physicians (ACP). Improving FDA Regulation of Prescription Drugs offers a half-dozen recommendations about how to improve the agency's ability to approve and monitor new drugs.

25 Sep 2009

Lifestyle choices affect the incidence and treatment of cancer

There is clear evidence that lifestyle choices affect the incidence and treatment of cancer, according to a study published in the current issue of American Journal of Lifestyle Medicine (AJLM).

25 Sep 2009

FA announces their Second Annual Fellowship Convention dates

Food Addicts in Recovery Anonymous (FA) announces their Second Annual Fellowship Convention to be held at the Santa Clara Marriot from October 16-18, 2009 in Santa Clara, California.

25 Sep 2009

Contribution of psychological characteristics to weight loss

Being too optimistic could harm weight loss efforts. Research published in BioMed Central's open access journal, BioPsychoSocial Medicine, reveals the psychological characteristics that may contribute to weight loss.

25 Sep 2009

SXC Health Solutions raises $203.3 million from public offering of its common shares

SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI, TSX: SXC) announced today that it successfully completed its previously announced public offering of 5,175,000 of its common shares at a price to the public of $41.50 per share, which includes 675,000 shares sold pursuant to the exercise of the underwriters' over-allotment option.

24 Sep 2009

Opexa Therapeutics' endeavor in the field of stem cell technology

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the company’s recently announced exclusive stem cell agreement with Novartis, one of the world’s largest healthcare companies. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa.

24 Sep 2009

Enrollment for pSivida's pilot FAVOR clinical study commences

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien in patients with macular edema secondary to retinal vein occlusion.

24 Sep 2009

Handheld diabetic test from MSGI's Nanobeak

MSGI Security Solutions Inc. (OTCBB: MSGI) today reported that the Company is launching its first product derived from NASA technology, a handheld test for Diabetes, which uses breath instead of blood.

24 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

MACH II clinical trial results revealed

Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced new clinical data from Academic Medical Center’s (AMC) three-year follow-up results from patients in the Impella 2.5 arm of the MACH II trial, revealing improved left ventricular function, cardiac output and quality of life.

24 Sep 2009

Hythiam raises $7 million from institutional investors

Hythiam, Inc. (NASDAQ:HYTM) announced today that on Tuesday, September 22, 2009 it closed the previously announced registered direct placement of 9,333,334 shares of its common stock to institutional investors at a price per share of $.75 for gross proceeds of $7 million.

24 Sep 2009

Interleukin Genetics reports positive results from clinical study on weight management

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today top-line positive results from a retrospective clinical study on weight management using patients who participated in a diet study previously reported in the Journal of the American Medical Association.

23 Sep 2009

Safeguard Scientifics sells additional 2.4 million shares of its position in Clarient

Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has sold an additional 2.4 million shares of its position in Clarient, Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form S-3 that was declared effective by the Securities and Exchange Commission on August 20, 2009.

23 Sep 2009

Online Investor Fact Sheet available: XerTech

XerTech Inc. (OTCBB:XTCH) a leading manufacturer, seller, and distributor of cutting-edge, interactive fitness systems for the commercial fitness, sporting goods, education, and healthcare industries, announces the availability of a new online Investor Fact Sheet.

23 Sep 2009

Nasdaq issues TLC Vision a noncompliance letter regarding minimum bid price

TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").

23 Sep 2009

Laura Creavalle, TotalTrainer announce partnership

TotalTrainer LLC, and trainer, fitness chef, cookbook author and former pro bodybuilder Laura Creavalle today announced a partnership whereby Laura Creavalle light and fit recipes will be made available via the TotalTrainer integrated training and nutrition platform for the club fitness industry.

23 Sep 2009

Pregnancy can cause metabolic syndrome

Childbearing is associated directly with future development of the metabolic syndrome - abdominal obesity, high triglycerides, insulin resistance and other cardiovascular disease risk factors - and for women who have had gestational diabetes, the risk is more than twice greater, according to a study co-authored by University of Alabama at Birmingham (UAB) researchers published in the American Journal of Obstetrics and Gynecology.

23 Sep 2009

Institutional investors offer 50 million for Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a focus primarily in oncology, today announced that it has received $50 million from existing institutional investors in a previously announced registered direct offering.

23 Sep 2009